VICI Properties Boosts 2025 AFFO Guidance Amid Strategic Moves

Published 7 hours agoVICI

VICI Properties Boosts 2025 AFFO Guidance Amid Strategic Moves

VICI Properties has adjusted its financial outlook upward, announcing an increase in its 2025 Adjusted Funds from Operations (AFFO) guidance. The real estate giant now expects AFFO for the year ending December 31, 2025, to range between $2.455 billion and $2.485 billion, translating to $2.32 to $2.35 per diluted common share. This revision suggests a projected growth of approximately 3.3% from the previous year, according to data from Fool.com.

Key to VICI's optimistic forecast are its strategic partnerships and investments. The company has joined forces with Cain International and Eldridge Industries, committing $300 million to a mezzanine loan for the development of One Beverly Hills. This move is part of VICI's broader strategy to tap into luxury hospitality and residential markets. In 2024 alone, VICI allocated over $1 billion in capital across various projects, which includes a substantial $250 million loan as part of a $1.55 billion financing package for Great Wolf Resorts, Inc.

Demonstrating resilience despite market fluctuations, VICI reported robust financial results for the fourth quarter of 2024, with revenues hitting $976.1 million, marking a 4.7% year-over-year increase. However, net income attributable to common stockholders decreased to $614.6 million, reflecting a 17.8% dip, largely due to changes in credit loss allowance. Nevertheless, adjusted funds from operations grew by 5.4% to $601.3 million, highlighting the company's ongoing ability to generate strong cash flows. These developments underscore VICI's strategic focus on enhancing its portfolio and operational efficiency.

Share this article

Twitter Facebook LinkedIn

Recent Articles

iRhythm Technologies Aims for $685 Million Revenue by 2025

iRhythm Technologies Aims for $685 Million Revenue by 2025

29 minutes agoIRTC

iRhythm Technologies has set a bold revenue target of $675 million to $685 million for 2025, as announced during its recent financial update. The company is focusing on expanding its reach in the healthcare sector through various strategic initiatives. One key strategy is targeting primary care physicians, which in 2023 accounted for about 21% of new U.S. Zio XT and Zio monitor registrations. Additionally, the company's Zio AT technology has advanced with FDA clearance for two 510(k) submissions, enhancing its capabilities. Reuters highlighted iRhythm's efforts to expand internationally, with ventures in four European countries, gaining Japanese regulatory approval, and forging a strategic partnership with BioIntelliSense. iRhythm is also integrating its systems with Epic Aura, having launched four healthcare systems in the fourth quarter of 2024, with broader plans for 2025. Moreover, the company has begun shipments of Zio monitors for home enrollment patients, aiming to improve service accessibility. These strategies collectively underpin iRhythm's ambitious 2025 revenue aspirations.

Dexcom Unveils Plans for Extended Wear G7 Glucose Monitor in 2025

Dexcom Unveils Plans for Extended Wear G7 Glucose Monitor in 2025

44 minutes agoDXCM

Dexcom has announced its plans to launch a new 15-day continuous glucose monitoring (CGM) system, the G7, in the second half of 2025. This comes on the heels of a robust first-quarter performance where revenue hit $921 million, showcasing a 24% increase from the previous year. The uptick in revenue is attributed to the growing demand for the G7 CGM system, known for its accuracy and enhanced user experience, as well as the FDA's approval of the direct-to-watch feature for the G7 and Stelo, a glucose biosensor tailored for non-insulin-dependent type 2 diabetes, according to Investing.com. The upcoming 15-day G7 system is currently under FDA review, with its market debut expected to further bolster Dexcom's earnings and improve their gross margins. As more users switch to the sensor with a longer wear time, the company's financial outlook remains positive. Fool.com notes that this strategic move aligns with Dexcom's broader goal of expanding its footprint in the CGM market, positioned to benefit user experience and financial outcomes. Dexcom has revised its revenue projections for 2025, now forecasting between $4.20 billion to $4.35 billion in revenue, suggesting an organic growth rate of 17% to 21%. The company anticipates reaching total revenues of $4.6 billion, marking a 14% increase year-over-year. With these strategies and the new product launch, Dexcom is well-placed to maintain its growth trajectory within the competitive diabetes management arena.

Universal Display Unveils 2025 Revenue Outlook and Strategic Developments

Universal Display Unveils 2025 Revenue Outlook and Strategic Developments

59 minutes agoOLED

Universal Display Corporation (UDC) recently outlined its financial expectations for 2025, projecting revenues between $640 million and $700 million. This projection indicates a careful approach amid the evolving landscape of the OLED industry. Additionally, UDC has declared a first-quarter 2025 cash dividend of $0.45 per share, payable on March 31, 2025, to shareholders on record as of March 17, 2025. In other developments, Universal Display is advancing its work on blue phosphorescent OLED (PHOLED) materials, which, despite taking longer than anticipated, are expected to reach commercialization in the coming months. This progress is significant for the OLED field. Moreover, UDC is restructuring its operations by closing its California-based OVJP center and setting up a new subsidiary, Universal Vapor Jet Corporation, in Singapore. This new entity will focus on commercializing its Organic Vapor Jet Printing technology, as reported by oled-info.com. These strategic moves illustrate UDC's dedication to innovation and growth within the OLED market. By enhancing its material development and restructuring its operations for efficient technology commercialization, UDC aims to solidify its position in the competitive OLED sector.

Amgen Projects Strong 2025 Revenue Growth with Expanding Product Pipeline

Amgen Projects Strong 2025 Revenue Growth with Expanding Product Pipeline

1 hours agoAMGN

Amgen has recently projected robust revenue growth for 2025, forecasting total revenues between $34.3 billion and $35.7 billion with adjusted earnings per share ranging from $20.00 to $21.20. This positive outlook comes as the company continues to advance its extensive product pipeline and expand into new therapeutic areas. Key drivers influencing Amgen's anticipated growth include several innovative therapies. The cholesterol-lowering drug Repatha, osteoporosis treatment EVENITY, and severe asthma therapy TEZSPIRE are all expected to contribute significantly to Amgen’s revenue. Furthermore, the company's oncology portfolio, rare disease treatments, and the launch of new biosimilars should bolster earnings. According to longportapp.com, Amgen's biosimilar portfolio, in particular, experienced a 16% increase in 2024, contributing to its optimistic outlook. Amgen's strategic interests also reflect heavy investment in research and development, with a planned increase of approximately 15% in R&D spending year-over-year. The focus will be on advancing therapies like MariTide, an obesity treatment preparing for Phase 3 trials in early 2025, as mentioned by Amgen. Additionally, Amgen has announced a significant $900 million expansion of its biotech manufacturing facility in Ohio, a move that Reuters reports will generate 750 new jobs and increase its total investment in the region to over $1.4 billion.